poisar

Stocks · News reference

Barinthus Biotherapeutics Q2 EPS $(0.26) Beats $(0.30) Estimate

Benzinga Newsdesk

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 50 percent increase over losses of $(0.52) per

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BRNS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Barinthus Biotherapeutics plc. (BRNS)

    Filed: 2026-09-09 AccNo: 0001104659-26-106183 Size: 272 KB Item 1.02: Termination of a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 9.01: Financial Statements and Exhibits

    BRNS